Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.68 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.68 |
| ▸ | KDM1A | O60341 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.68 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.68 |
| ▸ | XDH | P47989 | 1/20 | 0.68 |
| ▸ | IPMK | Q8NFU5 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | PLG | P00747 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 3/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8304881 | 1.00 | CYP1B1 (0.68) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 | |
| SCHEMBL4575622 | 1.00 | CYP1B1 (0.68) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 | |
| SCHEMBL8306291 | 0.94 | CYP1B1 (0.68) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 | |
| SCHEMBL4575095 | 0.93 | CYP1B1 (0.58) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 | |
| SCHEMBL4574696 | 0.93 | CYP1B1 (0.64) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 | |
| SCHEMBL8305042 | 0.89 | CYP1B1 (0.58) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 | |
| SCHEMBL8431111 | 0.88 | CYP1B1 (0.57) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 | |
| SCHEMBL8304688 | 0.87 | CYP1B1 (0.56) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 | |
| SCHEMBL4575595 | 0.87 | CYP1B1 (0.73) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 | |
| SCHEMBL4575135 | 0.86 | CYP1B1 (0.56) | CYP1B1CYP1A1KDM1ACYP1A2IP6K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0709383-B1 | Diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-12-15 | — | — | EP | claimed |
| US-5629339-A | CHRONIC VENOUS INSUFFICIENCY | ADIR ET COMPAGNIE (FR) | 1997-05-13 | — | — | US | claimed |
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | LES LABORATOIRES SERVIER (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | LES LABORATOIRES SERVIER (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | LES LABORATOIRES SERVIER (FR) | 2008-07-24 | — | — | US | disclosed |
| EP-1853253-A1 | DIOSMETIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF THROMBOTIC PATHOLOGIES | Les Laboratoires Servier (FR) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006092490-A1 | DIOSMETIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF THROMBOTIC PATHOLOGIES | LES LABORATOIRES SERVIER (FR) | 2006-09-08 | — | — | WO | disclosed |
| US-5629339-A | CHRONIC VENOUS INSUFFICIENCY | ADIR ET COMPAGNIE (FR) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176934-A1 | Use Of Diosmetin Compounds In The Treatment And Prevention Of Thrombotic Pathologies | ADAMTS13, ADAMTS1, SERPINC1 | CYP1B1 340/4885CYP1A1 545/4885KDM1A 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.